• Home
  • About Us
    • Company History
    • Our Scientific Approach
    • Other Approaches
    • Leadership
    • Board of Directors
    • Scientific Board
    • CLIA Laboratory
    • News
  • Products
    • Overview
    • MammoCheck
    • IGoCheck
    • Patient Information
    • Physician Information
    • Insurer Information
  • Pipeline Surveillance
    • Surveillance Overview
    • LuCheck
    • ProCheck
    • OvaCheck
  • Pipeline Early Detection
  • Research & Publications
  • Contact Us
  • Home
  • About Us
    • Company History
    • Our Scientific Approach
    • Other Approaches
    • Leadership
    • Board of Directors
    • Scientific Board
    • CLIA Laboratory
    • News
  • Products
    • Overview
    • MammoCheck
    • IGoCheck
    • Patient Information
    • Physician Information
    • Insurer Information
  • Pipeline Surveillance
    • Surveillance Overview
    • LuCheck
    • ProCheck
    • OvaCheck
  • Pipeline Early Detection
  • Research & Publications
  • Contact Us

A screening device for the early detection of cancer in the blood

Milagen developed and validated Igo4Check, a screening blood test for the early detection of the 4 major cancers: breast, colorectal, lung, and prostate. It is currently going through the regulatory process.


  • Pre-PMA submission was discussed with the FDA for the inclusion/exclusion criteria, the number of patients for each cancer type, and the intended use.


  • Igo4Check test is indicated for the screening of the average-risk asymptomatic population for the early detection of the 4 major cancers. Milagen is pursuing a Breakthrough Device designation with the FDA.

Copyright © 2022 Milagen Inc. - All Rights Reserved.


Website Info | Privacy Policy


This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.


California Users: You can decline cookies by clicking "Decline" below.

DeclineAccept